IMC Chicago
BBIO icon

IMC Chicago’s BridgeBio Pharma BBIO Stock Holding History

IMC Chicago’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4M Buy
53,800
+39,800
+284% +$2.88M ﹤0.01% 1984
2025
Q4 		$1.07M Buy
14,000
+2,700
+24% +$177K ﹤0.01% 2913
2025
Q3 		$587K Buy
+11,300
New +$551K ﹤0.01% 3072

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IMC Chicago's BBIO Position: Q3 2025 in Review

IMC Chicago sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 19,106 shares — an estimated $932K sold.

IMC Chicago first reported a position in BBIO in Q2 2025 and held it in 1 quarter. The position peaked at $825K in Q2 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • IMC Chicago reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
  • IMC Chicago sold 19,106 BridgeBio Pharma shares in Q3 2025, an estimated $932K.
  • IMC Chicago first reported a position in BridgeBio Pharma in Q2 2025 and held it in 1 quarter.
  • IMC Chicago's BridgeBio Pharma position peaked at $825K in Q2 2025.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on IMC Chicago's 13F filing for Q3 2025, filed 4 Nov 2025.